Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CYNTHIA C BRINSON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1093766396
CMS profile
49909
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$51,746.49

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CYNTHIA C BRINSON

NPI 1093766396 · CMS profile ID 49909

Allopathic & Osteopathic Physicians / Family Medicine

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093766396?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CYNTHIA C BRINSON, NPI 1093766396, CMS profile ID 49909. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093766396?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CYNTHIA C BRINSON, NPI 1093766396, CMS profile ID 49909. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093766396?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CYNTHIA C BRINSON, NPI 1093766396, CMS profile ID 49909, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1093766396?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $51,746.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $15.0005/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819873747 CMS
Gilead Sciences, Inc. $1,660.0005/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845852521 CMS
Merck Sharp & Dohme Corporation $23.0805/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848367233 CMS
ViiV Healthcare Company $3,600.0005/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803270009 CMS
Novo Nordisk Inc $8.5705/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811568703 CMS
Gilead Sciences, Inc. $1,660.0005/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845852519 CMS
Novartis Pharmaceuticals Corporation $13.5905/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812618363 CMS
Gilead Sciences, Inc. $15.6904/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848167639 CMS
ViiV Healthcare Company $2,760.0004/27/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803270295 CMS
Novo Nordisk Inc $14.5604/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811424685 CMS
ViiV Healthcare Company $122.0804/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803272227 CMS
ViiV Healthcare Company $1,200.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803270791 CMS
ViiV Healthcare Company $1,200.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803272949 CMS
ViiV Healthcare Company $6.7304/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803273435 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.8604/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819873745 CMS
Merck Sharp & Dohme Corporation $18.5404/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848590369 CMS
ViiV Healthcare Company $1,200.0004/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803271845 CMS
ViiV Healthcare Company $12.5704/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803273445 CMS
Gilead Sciences, Inc. $1,220.0003/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845852517 CMS
ViiV Healthcare Company $122.0703/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803271521 CMS
ViiV Healthcare Company $1,200.0003/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803271075 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5203/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763691128 CMS
Gilead Sciences, Inc. $30.0503/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848167637 CMS
Gilead Sciences, Inc. $510.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845881503 CMS
Novo Nordisk Inc $14.4603/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810911255 CMS
ViiV Healthcare Company $4,200.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803269915 CMS
ViiV Healthcare Company $3,600.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803269947 CMS
ViiV Healthcare Company $1,200.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803271237 CMS
ViiV Healthcare Company $1,200.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803272857 CMS
Astellas Pharma US Inc $18.6303/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821270155 CMS
Merck Sharp & Dohme Corporation $18.5403/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848641703 CMS
Gilead Sciences, Inc. $34.9503/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848167635 CMS
ViiV Healthcare Company $120.9202/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803269869 CMS
Gilead Sciences, Inc. $1,220.0002/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845852515 CMS
ViiV Healthcare Company $25.2802/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803272221 CMS
Amgen Inc. $12.3101/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825236313 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $101,560.13 156
PY2020 $24,620.45 35
PY2021 $51,746.49 86
PY2022 $52,256.86 112
PY2023 $83,088.41 150
PY2024 $40,606.69 63
PY2025 $48,480.51 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $290,991.34 48
PY2024 Principal investigator $900,248.99 148
PY2023 Recipient $2,999.92 17
PY2023 Principal investigator $1,216,043.89 233
PY2022 Recipient $250.26 2
PY2022 Principal investigator $3,039,187.77 240
PY2021 Recipient $47.90 1
PY2021 Principal investigator $3,797,444.12 404
PY2020 Recipient $141.90 1
PY2020 Principal investigator $2,362,565.27 586
PY2019 Recipient $1,206.97 11
PY2019 Principal investigator $1,924,293.63 351

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $374.35 12/22/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
NN9535-4352 No dispute reported 06/30/2026 1213792330
Principal investigator 1 ViiV Healthcare Company $8,221.59 11/24/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315543
Principal investigator 1 Exeltis, USA Inc. $800.00 11/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females No dispute reported 06/30/2026 1218193357
Principal investigator 1 Exeltis, USA Inc. $835.00 11/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females No dispute reported 06/30/2026 1218193362
Principal investigator 1 Exeltis, USA Inc. $1,000.00 11/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females No dispute reported 06/30/2026 1218193367
Principal investigator 1 Exeltis, USA Inc. $13,302.95 11/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females No dispute reported 06/30/2026 1218193370
Principal investigator 1 Gilead Sciences, Inc. $3,958.00 11/18/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217809
Principal investigator 1 ViiV Healthcare Company $1,633.32 11/18/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315595
Principal investigator 1 Novo Nordisk AS $374.35 10/29/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
NN9535-4352 No dispute reported 06/30/2026 1213710193
Principal investigator 1 Gilead Sciences, Inc. $4,097.00 10/21/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217799
Principal investigator 1 ViiV Healthcare Company $1,600.56 09/23/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315541
Principal investigator 1 Gilead Sciences, Inc. $843.00 09/16/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217788
Principal investigator 1 PFIZER INC. $330.00 09/05/2025 Non-covered Recipient Entity
Central Texas Clinical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228756089
Principal investigator 1 ViiV Healthcare Company $7,991.68 08/29/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315331
Principal investigator 1 ViiV Healthcare Company $5,105.88 08/29/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315333
Principal investigator 1 ABBVIE INC. $20,088.00 08/19/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202505089
Principal investigator 1 Gilead Sciences, Inc. $12,399.00 08/19/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217778
Principal investigator 1 Gilead Sciences, Inc. $7,089.00 07/22/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217769
Principal investigator 1 ViiV Healthcare Company $1,160.46 07/09/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315533
Principal investigator 1 Exeltis, USA Inc. $820.80 07/02/2025 Non-covered Recipient Entity
INTERSPOND LLC
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females No dispute reported 06/30/2026 1218192235
Principal investigator 1 ViiV Healthcare Company $3,827.66 06/22/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315329
Principal investigator 1 Gilead Sciences, Inc. $1,809.00 06/17/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217761
Principal investigator 1 Novo Nordisk AS $374.35 05/21/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
NN9535-4352 No dispute reported 06/30/2026 1213844013
Principal investigator 1 Gilead Sciences, Inc. $10,854.00 05/20/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217751
Principal investigator 1 ViiV Healthcare Company $7,034.04 05/16/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315339
Principal investigator 1 ViiV Healthcare Company $10,198.89 04/28/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315325
Principal investigator 1 Gilead Sciences, Inc. $4,097.00 04/22/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217741
Principal investigator 1 ViiV Healthcare Company $62,393.61 04/11/2025 Non-covered Recipient Entity
MOUNT SINAI SCHOOL OF MEDICINE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 1190315539
Principal investigator 1 Novo Nordisk AS $26,188.72 03/31/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
EX9924-4473 No dispute reported 06/30/2026 1213767320
Principal investigator 1 Exeltis, USA Inc. $1,480.00 03/28/2025 Non-covered Recipient Entity
INTERSPOND LLC
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females No dispute reported 06/30/2026 1218191485
Principal investigator 1 ViiV Healthcare Company $7,946.64 03/21/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315335
Principal investigator 1 ViiV Healthcare Company $6,032.30 03/21/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315535
Principal investigator 1 Gilead Sciences, Inc. $11,130.00 03/18/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217731
Principal investigator 1 ViiV Healthcare Company $242.20 03/12/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315529
Principal investigator 1 ABBVIE INC. $3,000.00 03/07/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202461506
Principal investigator 1 ViiV Healthcare Company $5,105.88 02/24/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315337
Principal investigator 1 Novo Nordisk AS $1,250.00 02/21/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
EX9924-4473 No dispute reported 06/30/2026 1213778983
Principal investigator 1 Gilead Sciences, Inc. $6,768.00 02/19/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217721
Principal investigator 1 PFIZER INC. $1,303.00 02/03/2025 Non-covered Recipient Entity
Central Texas Clinical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228775909
Principal investigator 1 PFIZER INC. $1,303.00 02/03/2025 Non-covered Recipient Entity
Central Texas Clinical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228776093
Principal investigator 1 PFIZER INC. $5,091.00 02/03/2025 Non-covered Recipient Entity
Central Texas Clinical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228777311
Principal investigator 1 PFIZER INC. $5,091.00 02/03/2025 Non-covered Recipient Entity
Central Texas Clinical Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228777718
Principal investigator 1 Novo Nordisk AS $1,144.40 01/31/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
NN9535-4352 No dispute reported 06/30/2026 1213847545
Principal investigator 1 Amgen Inc. $483.93 01/30/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease No dispute reported 06/30/2026 1246640175
Principal investigator 1 ViiV Healthcare Company $1,488.06 01/29/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315537
Principal investigator 1 ViiV Healthcare Company $3,528.72 01/28/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190315327
Principal investigator 1 ViiV Healthcare Company $720.00 01/28/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 1190315531
Principal investigator 1 Gilead Sciences, Inc. $9,081.00 01/22/2025 Non-covered Recipient Entity
CENTRAL TEXAS CLINICAL RESEARCH, LLC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217714